Limits...
Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.

Dalal P, Shah G, Chhabra D, Gallon L - Int J Nephrol Renovasc Dis (2010)

Bottom Line: Several new medications are now available for immunosuppression in the kidney transplant field.Tacrolimus and mycophenolate mofetil were first introduced for immunosuppression in renal transplantation in the mid 1990s.The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Mount Sinai Hospital, Chicago, Illinois, USA.

No MeSH data available.


Related in: MedlinePlus

Cell cycle with site of action of immunosupreessive drugs.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108777&req=5

f1-ijnrd-3-107: Cell cycle with site of action of immunosupreessive drugs.

Mentions: With the introduction and availability of several immunosuppressive drugs with different mechanisms of action, kidney transplantation has become the treatment of choice in end-stage renal disease. Immunosuppressive drugs are given to kidney transplant recipients in two phases, ie, induction and maintenance. The induction phase usually includes short courses of various antibodies against T lymphocytes, along with high doses of steroids. Four classes of drugs are available for maintenance immunosuppression, ie, corticosteroids, antimetabolites (azathioprine [AZA] and mycophenolate mofetil [MMF]/mycophenolate sodium), calcineurin inhibitors (cyclosporine [CSA] and tacrolimus [TAC]), and target of rapamycin inhibitors (sirolimus [SRL] and everolimus). The aim of maintenance immunosuppression is to avoid acute rejection, interstitial fibrosis and tubular atrophy (IFTA), and to improve overall graft and patient survival. Conventional immunosuppression regimens consist of various combinations of two or three agents from different groups. These drugs act on different phases of the cell cycle to inhibit either activation or proliferation of T lymphocytes (Figure 1), which are the major mediators of acute cellular rejection. Most of the aforementioned agents have several serious side effects which are usually related to dose and duration of treatment. The rationale for combining medications from different classes is to achieve adequate immunosuppression while limiting side effects. Different transplant centers in the US use different combinations of immunosuppressive medications during the maintenance phase, and no optimal immunosuppressive strategy has been determined as yet.


Role of tacrolimus combination therapy with mycophenolate mofetil in the prevention of organ rejection in kidney transplant patients.

Dalal P, Shah G, Chhabra D, Gallon L - Int J Nephrol Renovasc Dis (2010)

Cell cycle with site of action of immunosupreessive drugs.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108777&req=5

f1-ijnrd-3-107: Cell cycle with site of action of immunosupreessive drugs.
Mentions: With the introduction and availability of several immunosuppressive drugs with different mechanisms of action, kidney transplantation has become the treatment of choice in end-stage renal disease. Immunosuppressive drugs are given to kidney transplant recipients in two phases, ie, induction and maintenance. The induction phase usually includes short courses of various antibodies against T lymphocytes, along with high doses of steroids. Four classes of drugs are available for maintenance immunosuppression, ie, corticosteroids, antimetabolites (azathioprine [AZA] and mycophenolate mofetil [MMF]/mycophenolate sodium), calcineurin inhibitors (cyclosporine [CSA] and tacrolimus [TAC]), and target of rapamycin inhibitors (sirolimus [SRL] and everolimus). The aim of maintenance immunosuppression is to avoid acute rejection, interstitial fibrosis and tubular atrophy (IFTA), and to improve overall graft and patient survival. Conventional immunosuppression regimens consist of various combinations of two or three agents from different groups. These drugs act on different phases of the cell cycle to inhibit either activation or proliferation of T lymphocytes (Figure 1), which are the major mediators of acute cellular rejection. Most of the aforementioned agents have several serious side effects which are usually related to dose and duration of treatment. The rationale for combining medications from different classes is to achieve adequate immunosuppression while limiting side effects. Different transplant centers in the US use different combinations of immunosuppressive medications during the maintenance phase, and no optimal immunosuppressive strategy has been determined as yet.

Bottom Line: Several new medications are now available for immunosuppression in the kidney transplant field.Tacrolimus and mycophenolate mofetil were first introduced for immunosuppression in renal transplantation in the mid 1990s.The aim of this review is to analyze the literature critically and to provide an overview of tacrolimus and mycophenolate mofetil combination therapy in renal transplantation.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Mount Sinai Hospital, Chicago, Illinois, USA.

No MeSH data available.


Related in: MedlinePlus